KRAS and neoplasm: We treated the chemotherapy-naive PDX15, which was KRAS wild-type, with cetuximab as a monotherapy, and observed a reduction in tumor burden (Figure 6C), consistent with the predicted patient outcome based on clinical criteria for cetuximab treatment.